Get the Stockscreener App
9.51
1.06%
0.10
Amicus Therapeutics Inc stock is traded at $9.51, with a volume of 1.75M.
It is up +1.06% in the last 24 hours and down -2.96% over the past month.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$9.41
Open:
$9.5
24h Volume:
1.75M
Relative Volume:
0.70
Market Cap:
$2.84B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-27.97
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+3.26%
1M Performance:
-2.96%
6M Performance:
-8.38%
1Y Performance:
-20.95%
1-Day Range:
$9.395
$9.63
1-Week Range:
$9.115
$9.63
52-Week Range:
$8.785
$14.03
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.51 | 2.84B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Q2 Earnings Forecast for FOLD Issued By Leerink Partnrs - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
Jefferies Initiates Coverage of Amicus Therapeutics (FOLD) with Buy Recommendation - MSN
Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Enzyme Replacement Therapy Market Deep Research Report with - openPR
When (FOLD) Moves Investors should Listen - Stock Traders Daily
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.88 - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpStill a Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC - MarketBeat
Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - MSN
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts - Benzinga
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week - Yahoo Finance
Fabry Disease Treatment Market Top Companies StudySanofi SA, - openPR
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - GlobeNewswire
Amicus Therapeutics Reports Stellar 32% Revenue Growth to $528.5M, Eyes $1B Sales Target - StockTitan
Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Canada
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year LowShould You Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at $9.01 - Investing.com
Principal Financial Group Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - MarketBeat
How the (FOLD) price action is used to our Advantage - Stock Traders Daily
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Amicus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
JPMorgan Chase & Co. Sells 1,984,751 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co. - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update - MarketBeat
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues - Simply Wall St
Amicus Therapeutics: Cheap Heading Into 2025 (NASDAQ:FOLD) - Seeking Alpha
Stifel Financial Corp Sells 21,615 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Geode Capital Management LLC Acquires 80,926 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat
Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2%Time to Buy? - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – Here’s What Happened - Defense World
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):